Wikipedia -WSS

Wikipedia

author：focus 2025-09-04 22:17:28 - browse：695

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Psilocybin's anti

hotspot

WSS

Pharmacists can make shortage drugs, but at what cost?

CEOs share strategies for surviving biotech slump

First Opinion Podcast: Long Covid needs a new approach

Lawmakers consider Medicare pay reforms for doctors

Lawmakers consider Medicare pay reforms for doctors

Pharmacists can make shortage drugs, but at what cost?

focus

Wikipedia

Wikipedia

Drug repurposing or repositioning? The language matters

Researchers explore possible ties between long Covid, menopause

New air purifier tech could be key to improving indoor air quality

Eli Lilly expects to double planned employment in Boston center

Duchenne breakthrough therapy leaves behind pioneering families

Medicare explains how it will choose drugs for negotiation

Dobbs anniversary: the lost opportunity of abortion as health care

Feds fine Medicare Advantage plans for overcharging members

Drug repurposing or repositioning? The language matters

Why health workers in Gaza are injured or die at high rates

focus

Complete sequence of Y chromosome published for first time

Eli Lilly expects to double planned employment in Boston center

Beam Therapeutics to lay off 20% of its staff, re

Neuroscience startup Neumora files for IPO

CDC advisory panel says seniors 'may' get RSV vaccine

AstraZeneca bets AAV gene therapy will still deliver the goods

focus

hotspot

knowledge

leisure time